Premium
Corcept Therapeutics Inc (1CORT)
BIT
Hot Features
Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
| Date | Nom du détenteur | Actions transigées | Fourchette de valeur ($) | Type d'opération | Fourchette de prix ($) | Actions en fin de déclaration | % de variation |
|---|---|---|---|---|---|---|---|
| 2026-06-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -12,84k | 895,25k | Automatic Disposition | 69,74 | 2,87M | -0,45% |
| 2026-05-29 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -300,00k | 0,00 | Other Disposition | - | 2,87M | -9,48% |
| 2026-05-27 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 325,00k | Vente | 65,00 | 6,23k | -44,52% |
| 2026-05-13 | Mr. Gary Charles RobbChief Business Officer & Secretary | -5,30k | 0,00 | Other Disposition | - | 99,35k | -5,06% |
| 2026-05-05 | Dr. William GuyerChief Development Officer | -20,00k | 603,60k | Derivative Exercise and Sale | 21,65 - 51,83 | 2,23k | - |
| 2026-05-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,00M | Automatic Disposition | 50,10 | 2,88M | -1,37% |
| 2026-04-22 | Mr. James N. WilsonIndependent Chairman | -2,00k | 0,00 | Other Disposition | - | 2,40M | -0,08% |
| 2026-04-07 | Dr. William GuyerChief Development Officer | -20,00k | 386,40k | Derivative Exercise and Sale | 21,65 - 40,97 | 2,23k | - |
| 2026-04-06 | Mr. James N. WilsonIndependent Chairman | -5,00k | 0,00 | Other Disposition | - | 2,40M | -0,21% |
| 2026-03-25 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -26,20k | 1,31M | Automatic Disposition | 50,07 | 2,92M | -0,89% |
| 2026-03-20 | Mr. James N. WilsonIndependent Chairman | -4,00k | 0,00 | Other Disposition | - | 2,40M | -0,17% |
| 2026-03-20 | Dr. William GuyerChief Development Officer | -11,77k | 168,97k | Derivative Exercise and Sale | 21,65 - 36,01 | 2,23k | - |
| 2026-03-17 | Mr. George Leonard BakerIndependent Director | 100,00k | 3,31M | Achat | 33,00 - 33,56 | 5,55M | 1,83% |
| 2026-03-13 | Mr. James N. WilsonIndependent Chairman | -28,00k | 0,00 | Other Disposition | - | 2,41M | -1,15% |
| 2026-03-13 | Mr. David L. MahoneyIndependent Director | -30,00k | 28,35 | Derivative Exercise and Sale | 5,86 - 32,15 | 1,28M | - |
| 2026-03-04 | Dr. William GuyerChief Development Officer | -8,23k | 118,10k | Derivative Exercise and Sale | 21,65 - 35,99 | 2,23k | - |
| 2026-03-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -89,00 | 3,20k | Sale to Issuer | 35,97 | 11,23k | -0,79% |
| 2026-03-03 | Mr. Sean MaduckPresident of Endocrinology | -110,00 | 3,96k | Sale to Issuer | 35,97 | 118,69k | -0,09% |
| 2026-03-03 | Mr. Gary Charles RobbChief Business Officer & Secretary | -121,00 | 4,35k | Sale to Issuer | 35,97 | 102,65k | -0,12% |
| 2026-03-03 | Mr. Atabak MokariCFO & Treasurer | -96,00 | 3,45k | Sale to Issuer | 35,97 | 15,26k | -0,63% |
| 2026-02-24 | Mr. James N. WilsonIndependent Chairman | -100,00k | 1,28 | Derivative Exercise and Sale | 3,88 - 36,48 | 2,44M | - |
| 2026-01-08 | Mr. Sean MaduckPresident of Endocrinology | -54,57k | 0,00 | Other Disposition | - | 117,90k | -31,64% |
| 2026-02-09 | Dr. Hazel HuntChief Scientific Officer | 72,03k | 279,48k | Derivative Exercise and Retained Stock | 3,88 | 255,44k | 39,27% |
| 2026-02-09 | Dr. Hazel HuntChief Scientific Officer | -77,97k | 2,92M | Derivative Exercise and Sale | 3,88 - 41,31 | 255,44k | - |
| 2026-02-03 | Dr. William GuyerChief Development Officer | -20,00k | 384,33k | Derivative Exercise and Sale | 21,65 - 40,87 | 1,24k | - |
| 2026-01-27 | Mr. George Leonard BakerIndependent Director | 140,00k | 1,61M | Derivative Exercise and Retained Stock | 5,86 - 15,15 | 5,45M | 2,64% |
| 2026-01-06 | Dr. William GuyerChief Development Officer | -20,00k | 270,66k | Derivative Exercise and Sale | 21,65 - 35,18 | 1,24k | - |
| 2026-01-01 | Mr. George Leonard BakerIndependent Director | 0,00 | 0,00 | Other Disposition | - | 5,31M | 0,00% |
| 2025-12-24 | Mr. Gary Charles RobbChief Business Officer & Secretary | 64,72k | 251,10k | Derivative Exercise and Retained Stock | 3,88 | 101,77k | 174,66% |
| 2025-12-24 | Mr. Gary Charles RobbChief Business Officer & Secretary | -80,28k | 6,40M | Derivative Exercise and Sale | 3,88 - 83,59 | 101,77k | - |
| 2025-12-24 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -550,00k | 23,52M | Derivative Exercise and Sale | 3,88 - 83,59 | 2,94M | - |
| 2025-12-12 | Mr. James N. WilsonIndependent Chairman | -400,00k | 0,00 | Other Disposition | - | 2,35M | -14,57% |
| 2025-12-02 | Dr. William GuyerChief Development Officer | -20,00k | 1,17M | Derivative Exercise and Sale | 21,65 - 80,88 | 1,24k | - |
| 2025-12-02 | Dr. William GuyerChief Development Officer | -787,00 | 0,00 | Other Disposition | - | 1,24k | -38,92% |
| 2025-12-01 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,43M | Derivative Exercise and Sale | 8,27 - 79,52 | 117,90k | - |
| 2025-12-02 | Mr. Sean MaduckPresident of Endocrinology | -135,00 | 10,77k | Sale to Issuer | 79,78 | 117,90k | -0,11% |
| 2025-12-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 329,83k | Derivative Exercise and Sale | 13,56 - 79,53 | 10,52k | - |
| 2025-12-02 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -110,00 | 8,78k | Sale to Issuer | 79,78 | 10,52k | -1,03% |
| 2025-12-02 | Mr. Atabak MokariCFO & Treasurer | -118,00 | 9,41k | Sale to Issuer | 79,78 | 14,56k | -0,80% |
| 2025-12-02 | Mr. Gary Charles RobbChief Business Officer & Secretary | -148,00 | 11,81k | Sale to Issuer | 79,78 | 37,05k | -0,40% |
| 2025-12-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 3,19M | Automatic Disposition | 79,77 | 2,70M | -1,46% |
| 2025-11-25 | Dr. William GuyerChief Development Officer | -4,50k | 364,07k | Vente | 80,90 | 787,00 | -85,11% |
| 2025-11-17 | Dr. William GuyerChief Development Officer | -5,29k | 0,00 | Other Disposition | - | 787,00 | -87,04% |
| 2025-11-05 | Dr. William GuyerChief Development Officer | -20,00k | 1,07M | Derivative Exercise and Sale | 21,65 - 76,28 | 5,29k | - |
| 2025-11-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 300,44k | Derivative Exercise and Sale | 13,56 - 73,65 | 10,28k | - |
| 2025-11-03 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,98M | Automatic Disposition | 74,08 - 75,98 | 2,74M | -1,44% |
| 2025-11-03 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,31M | Derivative Exercise and Sale | 8,27 - 73,99 | 117,62k | - |
| 2025-10-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 161,61k | Derivative Exercise and Sale | 14,08 - 87,54 | 0,00 | - |
| 2025-10-07 | Dr. William GuyerChief Development Officer | -20,00k | 1,37M | Derivative Exercise and Sale | 21,65 - 89,94 | 5,29k | - |
| 2025-10-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 3,40M | Automatic Disposition | 84,29 - 85,67 | 2,78M | -1,42% |
| 2025-10-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 355,97k | Derivative Exercise and Sale | 13,56 - 85,39 | 10,28k | - |
| 2025-10-01 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,54M | Derivative Exercise and Sale | 5,05 - 85,58 | 117,62k | - |
| 2025-09-19 | Dr. William GuyerChief Development Officer | -200,00 | 0,00 | Other Disposition | - | 5,29k | -3,64% |
| 2025-09-10 | Dr. Gillian M. CannonInitié | -7,39k | 0,00 | Other Disposition | - | 0,00 | -100,00% |
| 2025-09-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 128,41k | Derivative Exercise and Sale | 14,08 - 72,45 | 0,00 | - |
| 2025-09-04 | Dr. Gillian M. CannonInitié | 7,39k | 169,97k | Derivative Exercise and Retained Stock | 22,99 | 7,39k | - |
| 2025-09-04 | Dr. Gillian M. CannonInitié | -3,61k | 170,03k | Derivative Exercise and Sale | 22,99 - 70,13 | 7,39k | - |
| 2025-09-02 | Dr. William GuyerChief Development Officer | -20,00k | 976,85k | Derivative Exercise and Sale | 21,65 - 70,85 | 5,49k | - |
| 2025-09-02 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 283,45k | Derivative Exercise and Sale | 13,56 - 70,76 | 10,28k | - |
| 2025-09-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -189,00 | 13,49k | Sale to Issuer | 71,38 | 10,28k | -1,81% |
| 2025-09-02 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,31M | Derivative Exercise and Sale | 5,05 - 70,84 | 117,62k | - |
| 2025-09-03 | Mr. Sean MaduckPresident of Endocrinology | -233,00 | 16,63k | Sale to Issuer | 71,38 | 117,62k | -0,20% |
| 2025-09-02 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,82M | Automatic Disposition | 70,52 - 71,01 | 2,82M | -1,40% |
| 2025-09-03 | Mr. Atabak MokariCFO & Treasurer | -144,00 | 10,28k | Sale to Issuer | 71,38 | 14,32k | -1,00% |
| 2025-09-03 | Mr. Gary Charles RobbChief Business Officer & Secretary | -256,00 | 18,27k | Sale to Issuer | 71,38 | 36,75k | -0,69% |
| 2025-08-22 | Mr. Gary Charles RobbChief Business Officer & Secretary | -5,00k | 336,68k | Derivative Exercise and Sale | 3,88 - 71,27 | 36,51k | - |
| 2025-08-11 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 128,08k | Derivative Exercise and Sale | 14,08 - 72,30 | 0,00 | - |
| 2025-08-08 | Dr. William GuyerChief Development Officer | -35,01k | 1,75M | Derivative Exercise and Sale | 21,65 - 71,77 | 5,49k | - |
| 2025-08-05 | Dr. William GuyerChief Development Officer | -14,00 | 701,68 | Derivative Exercise and Sale | 21,65 - 71,77 | 5,49k | - |
| 2025-08-01 | Mr. Sean MaduckPresident of Endocrinology | -35,01k | 2,20M | Derivative Exercise and Sale | 5,05 - 69,70 | 117,40k | - |
| 2025-06-12 | Mr. Sean MaduckPresident of Endocrinology | -50,02k | 0,00 | Other Disposition | - | 117,40k | -29,88% |
| 2025-08-01 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 2,74M | Automatic Disposition | 67,81 - 69,65 | 2,86M | -1,38% |
| 2025-08-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,82k | 314,17k | Derivative Exercise and Sale | 13,56 - 67,51 | 10,07k | - |
| 2025-07-17 | Mr. Sean MaduckPresident of Endocrinology | -4,79k | 327,61k | Derivative Exercise and Sale | 5,05 - 73,48 | 117,40k | - |
| 2025-07-17 | Dr. William GuyerChief Development Officer | -4,88k | 252,86k | Derivative Exercise and Sale | 21,65 - 73,48 | 5,49k | - |
| 2025-07-17 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -4,08k | 244,26k | Derivative Exercise and Sale | 13,56 - 73,48 | 10,07k | - |
| 2025-07-17 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -615,00 | 45,32k | Automatic Disposition | 73,69 | 2,90M | -0,02% |
| 2025-07-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 125,40k | Derivative Exercise and Sale | 14,08 - 71,08 | 0,00 | - |
| 2025-07-01 | Dr. William GuyerChief Development Officer | -100,00 | 5,19k | Derivative Exercise and Sale | 21,65 - 73,51 | 5,49k | - |
| 2025-07-01 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -100,00 | 5,99k | Derivative Exercise and Sale | 13,56 - 73,51 | 10,07k | - |
| 2025-07-01 | Mr. Sean MaduckPresident of Endocrinology | -205,00 | 14,02k | Derivative Exercise and Sale | 5,05 - 73,45 | 117,40k | - |
| 2025-06-16 | Mr. Gary Charles RobbChief Business Officer & Secretary | -3,19k | 225,40k | Vente | 70,77 | 36,51k | -8,02% |
| 2025-06-10 | Mr. Daniel N. SwisherIndependent Director | -2,20k | 124,37k | Derivative Exercise and Sale | 14,08 - 70,61 | 0,00 | - |
| 2025-06-10 | Dr. William GuyerChief Development Officer | -20,00k | 1,02M | Derivative Exercise and Sale | 21,65 - 72,75 | 5,49k | - |
| 2025-06-02 | Dr. Joseph K. BelanoffCo-Founder, President, CEO & Director | -40,00k | 3,31M | Automatic Disposition | 78,42 - 85,01 | 2,90M | -1,36% |
| 2025-06-02 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -5,00k | 322,42k | Derivative Exercise and Sale | 13,56 - 78,65 | 10,07k | - |
| 2025-06-03 | Mr. Joseph Douglas LyonChief Technology & Accounting Officer | -441,00 | 31,61k | Sale to Issuer | 71,68 | 10,07k | -4,20% |
| 2025-06-03 | Mr. Gary Charles RobbChief Business Officer & Secretary | -651,00 | 46,66k | Sale to Issuer | 71,68 | 39,69k | -1,61% |
| 2025-06-02 | Mr. Sean MaduckPresident of Endocrinology | -20,00k | 1,48M | Derivative Exercise and Sale | 5,05 - 80,77 | 117,40k | - |
| 2025-06-03 | Mr. Atabak MokariCFO & Treasurer | -519,00 | 37,20k | Sale to Issuer | 71,68 | 14,07k | -3,56% |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
S'inscrire avec l'e-mail
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.
